Rat Target Sites | Mouse Target Sites | TD50 (mg/kg/day) | |||
Male | Female | Male | Female | Rat | Mouse |
eso kid liv vsc | eso liv orc sto | no test | no test | 0.0265m,v | no test |
Monkey Target Sites | TD50 (mg/kg/day) |
||
Rhesus | Cynomulgus | Rhesus | Cynomulgus |
liv | liv | 0.0536m,v | 0.00725m,v |
Target Sites | TD50 (mg/kg/day) |
nas | 0.0122i |
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
N-NITROSODIETHYLAMINE (DEN) 55-18-5 4508 N b bbb ipj 32m32 2001s : () 0 .897mg Adamson;ossc,129-156;1982/Thorgeirsson 1994/Dalgard 1997/ Thorgeirsson&Seiber pers.comm. nac mec jw 12.2ug P<.0005 + 3.36ug 46.0ug 0/9 10/13 liv hpc jw 18.4ug P<.008 3.57ug 1.03mg 0/9 2/3 tba mal Wjw 12.2ug P<.0005 3.36ug 46.0ug 0/9 10/13 4509 P b cym ipj 16y16 2004m : 0 6.30ug .322mg .910mg 1.35mg 2.29mg liv hpc jw 3.63ug * P<.0005 + 944.ng 22.0ug 0/105 2/7 3/3 5/5 5/5 38/40 tba mal Wjw 3.63ug * P<.0005 944.ng 22.0ug 0/105 2/7 3/3 5/5 5/5 38/40 4510 P b cym eat 16y16 2004n : 0 8.07mg liv hpc jw 2.08mg P<.0005 + 1.01mg 4.45mg 0/104 13/16 tba mal Wjw 2.08mg P<.0005 1.01mg 4.45mg 0/104 13/16 4511 P b rhe ipj 20y20 2004m : 0 7.40ug 80.0ug .340mg .650mg 1.59mg 2.09mg liv hpc jw 27.1ug * P<.0005 + 10.1ug 59.9ug 0/120 0/4 4/8 6/6 5/5 6/6 51/53 liv bda jw 27.0ug * P<.02 4.40ug n.s.s. 0/23 -/- 1/1 -/- -/- -/- -/- tba mix Wjw 21.6ug * P<.0005 8.79ug 43.7ug 9/120 0/4 5/8 6/6 5/5 6/6 51/53 tba mal Wjw 24.7ug * P<.0005 9.66ug 55.5ug 4/120 0/4 4/8 6/6 5/5 6/6 51/53 tba ben Wjw no dre P=1. .130mg n.s.s. 6/108 0/4 1/8 0/6 0/5 0/6 0/45 4512 P b rhe eat 22y22 2004n : 0 6.87mg liv hpc jw 2.62mg P<.0005 + 1.04mg 5.88mg 0/102 11/14 tba mal Wjw 1.59mg P<.0005 .620mg 4.89mg 5/102 11/14 4513 R f clw wat 41m41 2259 : 0 2.00ug 4.00ug 9.00ug 18.0ug 36.0ug 72.0ug .107mg .143mg .179mg .215mg .287mg .358mg .430mg .573mg 1.15mg Peto;canr,51,6415-5451;1991a/Peto 1991b liv mxp 49.8ug Z P<.0005 + 37.5ug 64.7ug 16/240 6/60 4/60 4/60 7/60 12/60 35/60 44/60 47/66 47/60 46/60 49/60 52/60 52/60 57/60 50/54 liv hct 61.5ug Z P<.0005 + 46.6ug 80.8ug 11/240 4/60 4/60 3/60 4/60 10/60 31/60 42/60 45/66 45/60 45/60 48/60 50/60 52/60 57/60 45/54 liv hpc .105mg Z P<.0005 + 75.3ug .139mg 2/240 0/60 2/60 1/60 3/60 3/60 22/60 39/60 37/66 44/60 43/60 46/60 47/60 50/60 56/60 44/54 eso mix .203mg Z P<.0005 + .162mg .250mg 0/240 0/60 0/60 0/60 0/60 3/60 19/60 21/60 32/66 29/60 42/60 37/60 44/60 41/60 36/60 26/54 liv bdh .561mg * P<.0005 .200mg 2.73mg 4/240 2/60 0/60 1/60 2/60 1/60 2/60 2/60 2/66 0/60 0/60 0/60 1/60 0/60 0/60 0/54 liv bdb .562mg * P<.0005 .210mg 2.63mg 3/240 2/60 0/60 1/60 2/60 1/60 2/60 2/60 2/66 0/60 0/60 0/60 1/60 0/60 0/60 0/54 eso mal .729mg Z P<.0005 + .531mg .992mg 0/240 0/60 0/60 0/60 0/60 0/60 2/60 8/60 16/66 11/60 15/60 11/60 18/60 13/60 12/60 11/54 liv bdm no dre P=1. .657mg n.s.s. 1/240 0/60 0/60 0/60 0/60 0/60 0/60 0/60 0/66 0/60 0/60 0/60 0/60 0/60 0/60 0/54 4514 R m clw wat 40m40 2259 : 0 1.00ug 3.00ug 5.00ug 10.0ug 20.0ug 41.0ug 61.0ug 82.0ug .102mg .122mg .163mg .204mg .245mg .326mg .653mg liv mxp 52.0ug Z P<.0005 + 37.3ug 72.1ug 13/240 4/60 2/60 9/60 4/60 7/60 15/60 25/60 15/60 25/60 26/60 31/60 29/60 35/60 30/60 48/60 liv hct 92.4ug Z P<.0005 + 62.4ug .133mg 10/240 1/60 2/60 3/60 0/60 5/60 9/60 18/60 10/60 21/60 20/60 23/60 27/60 28/60 28/60 47/60 eso mix 94.9ug Z P<.0005 + 77.7ug .115mg 0/240 0/60 0/60 0/60 0/60 3/60 16/60 32/60 37/60 45/60 48/60 41/60 49/60 46/60 47/60 46/60 liv hpc .136mg Z P<.0005 + 89.6ug .198mg 4/240 0/60 0/60 1/60 0/60 5/60 7/60 16/60 8/60 18/60 20/60 21/60 27/60 28/60 28/60 47/60 eso mal .236mg Z P<.0005 + .185mg .300mg 0/240 0/60 0/60 0/60 0/60 0/60 3/60 14/60 23/60 25/60 30/60 20/60 25/60 21/60 25/60 20/60 liv bdh .372mg * P<.0005 .150mg 1.15mg 3/240 2/60 0/60 1/60 2/60 0/60 4/60 3/60 1/60 2/60 2/60 2/60 1/60 0/60 0/60 0/60 liv bdb .419mg * P<.0005 .160mg 1.50mg 3/240 2/60 0/60 1/60 2/60 0/60 3/60 2/60 1/60 2/60 2/60 2/60 1/60 0/60 0/60 0/60 nsp mix 2.74mg * P<.0005 .967mg 9.63mg 0/240 0/60 0/60 0/60 0/60 0/60 2/60 1/60 1/60 1/60 0/60 1/60 1/60 0/60 0/60 0/60 liv bdm 5.87mg * P<.02 1.38mg n.s.s. 0/240 0/60 0/60 0/60 0/60 0/60 1/60 1/60 0/60 0/60 0/60 0/60 0/60 0/60 0/60 0/60 4515 R f f34 wat 7m30 1173m 0 4.40ug 10.4ug 26.4ug .119mg .538mg Lijinsky;canr,41,4997-5003;1981/ pers.comm. eso mix 25.5ug Z P<.0005 + 14.7ug 48.3ug 0/20 0/20 3/20 18/19 (13/20 10/12) liv hpc no dre P=1. + 1.53mg n.s.s. 0/20 1/20 5/20 5/19 1/20 1/12 ton bcc no dre P=1. + 2.24mg n.s.s. 0/20 0/20 1/20 6/19 0/20 0/12 4516 R f f34 wat 14m30 1173n 0 8.48ug 20.7ug liv mix 7.87ug \ P<.0005 + 3.92ug 20.0ug 1/20 14/20 (5/20) eso mix 20.7ug / P<.0005 + 11.7ug 40.8ug 0/20 2/20 17/20 4517 R f f34 wat 24m30 1173o 0 14.8ug mix mix 13.1ug P<.0005 + 6.70ug 29.5ug 0/20 14/20 eso mix 15.0ug P<.0005 + 7.61ug 34.8ug 0/20 13/20 for bcp 54.9ug P<.007 + 20.7ug .633mg 0/20 5/20 liv mix 41.6ug P<.02 + 16.4ug n.s.s. 1/20 7/20 4518 R f f34 wat 30w65 1561 0 .132mg Lijinsky;fctx,21,601-605;1983 eso tum 21.9ug P<.0005 + 11.2ug 47.7ug 0/20 16/20 liv tum no dre P=1. .127mg n.s.s. 1/20 1/20 tba tum no dre P=1. 16.1ug n.s.s. 20/20 18/20 4519 R f fis wat 86w86 1041 0 51.6ug Nixon;jnci,53,453-458;1974 liv hpt e no dre P=1. - .109mg n.s.s. 0/15 0/15 tba mix e no dre P=1. - .109mg n.s.s. 3/15 0/15 4520 R m fis wat 86w86 1041 0 46.0ug liv hpt e no dre P=1. - 84.3ug n.s.s. 0/16 0/13 tba tum e no dre P=1. - 84.3ug n.s.s. 0/16 0/13 4521 R m sda wat 27m27 1303 0 71.4ug Habs;onco,37,259-265;1980 mix tum 70.6ug P<.0005 + 49.8ug .104mg 0/90 52/90 liv tum .119mg P<.0005 + 79.4ug .190mg 0/90 36/90 eso tum .133mg P<.0005 + 87.4ug .217mg 0/90 33/90 4522 R m sda wat 35m37 1838 0 7.14ug 22.9ug 71.4ug Berger;carc,8,1635-1643;1987/pers.comm. liv mix a .270mg Z P<.0005 + .183mg .422mg 3/500 2/80 3/80 36/80 git mix a .401mg * P<.0005 + .241mg .807mg 26/500 9/80 7/80 25/80 liv hpc a .541mg Z P<.0005 + .326mg .991mg 0/500 1/80 0/80 21/80 eso pam a .715mg Z P<.0005 + .405mg 1.44mg 0/500 0/80 0/80 17/80 liv hmm a .719mg * P<.0005 + .408mg 1.45mg 0/500 0/80 2/80 15/80 eso sqc a 3.38mg * P<.002 + 1.13mg 26.3mg 1/500 0/80 0/80 4/80 unt tum a 6.51mg * P<.3 + 1.32mg n.s.s. 1/500 2/80 1/80 1/80 tba mal a .188mg * P<.0005 + .118mg .370mg 144/500 23/80 27/80 52/80 tba ben a no dre P=1. .368mg n.s.s. 362/500 58/80 54/80 53/80 4523 R f wio wat 60w63 1041 0 .136mg Nixon;jnci,53,453-458;1974 liv hpt e 49.3ug P<.0005 + 23.5ug .131mg 0/18 10/20 tba mix e 53.7ug P<.002 24.3ug .262mg 1/18 10/20 4524 R m wio wat 60w63 1041 0 .104mg liv hpt e .104mg P<.02 + 35.9ug n.s.s. 0/17 4/18 tba mix e .104mg P<.02 35.9ug n.s.s. 0/17 4/18 4525 R f wis gav 28m28 1399 0 10.2ug Kroes;fctx,12,671-679;1974 mgl adc e .127mg P<.08 - 41.5ug n.s.s. 1/59 5/58 liv hnd e 31.3mg P<1. - 98.7ug n.s.s. 1/59 1/58 tba ben e 35.5ug P<.08 - 13.6ug n.s.s. 18/59 27/58 tba mal e 4.01mg P<1. - 47.3ug n.s.s. 7/59 7/58 4526 R m wis gav 28m28 1399 0 7.14ug liv tum e no dre P=1. - 78.4ug n.s.s. 0/39 0/40 tba mal e 77.4ug P<.4 - 18.1ug n.s.s. 4/39 7/40 tba ben e .257mg P<.9 - 18.2ug n.s.s. 8/39 9/40
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.